Mansonelliasis

Summary

Mansonelliasis (MONDO:0005838) is a disease and 3 clinical trials. Top therapeutic interventions include albendazole and diethylcarbamazine. A subtype of Rhabditida infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)
• Clinical trials: 3

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	<1 / 1 000 000		Europe	Not yet validated

Identifiers

Disease identifiers

Field	Value
Canonical name	mansonelliasis
Mondo ID	MONDO:0005838
EFO	EFO:0007357
MeSH	D004154, D008368
Orphanet	2459
DOID	DOID:1081, DOID:14422
ICD-10-CM	B74.4
ICD-11	1504434405
NCIT	C34540, C84882
SNOMED CT	15629006, 240849009
UMLS	C0024759
MedGen	6213
GARD	0008216
Is cancer (heuristic)	no

Also known as: Acanthocheilonema perstans infection · Acanthocheilonemiasis · Dipetalonema infection · Dipetalonema infections · dipetalonemiasis · infection by Dipetalonema perstans (disorder) [ambiguous] · Mansonella perstans · Mansonella perstans caused disease or disorder · Mansonella perstans infections · Mansonellosis

Disease family

This is a subtype of Rhabditida infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › helminthiasis › Nematoda infectious disease › Rhabditida infectious disease › mansonelliasis

Related subtypes (11): thelaziasis, ancylostomiasis, Ascaridida infectious disease, enterobiasis, oesophagostomiasis, setariasis, strongyloidiasis, trichostrongylosis, dirofilariasis, dracunculiasis, onchocerciasis

Subtypes (1): Mansonella ozzardi infection

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00001230	Not specified	RECRUITING	Host Response to Infection and Treatment in Filarial Diseases
NCT06350851	Not specified	RECRUITING	Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
NCT00215280	Not specified	COMPLETED	Epidemiology and Control of Mansonella Perstans Infection in Uganda

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ALBENDAZOLE	4	1
DIETHYLCARBAMAZINE	4	1
CHEMBL263291	0	1